Personnel changes!

01 Business adjustment of pharmaceutical giants

Since 2022, many well-known pharmaceutical companies have announced personnel adjustment plans under pressure from various aspects, reducing non-core business personnel to save development funds

On February 5, Sanofi CEO Paul Hudson (Paul Hudson) announced that it is expected to reduce about 6,000 people and adjust the research and development pipeline

Paul Hudson said Sanofi is embracing digital change, streamlining its product portfolio and working with geographic partners to balance and reduce infrastructure while improving access to medicines

The business adjustment mainly includes the spin-off plan of EUROAPI (API company) and the termination of cooperation with Sangamo Therapeutics (biopharmaceutical company) to develop personalized cell therapy

On January 12, according to Reuters news, Pfizer is expected to reduce its sales force in the United States after the end of the epidemic

One can see the reasons for digitization and business realignment or downsizing in big pharma

For example, Ji Liwen, President of Lilly China, mentioned in a media interview that the future market for sintilimab will expand from large hospitals to small and medium-sized medical institutions, and Lilly will re-divide labor with Cinda

02 Innovative pharmaceutical companies break their arms to survive

If it is said that the adjustment of large pharmaceutical companies is for better development, the personnel adjustment of small biopharmaceutical companies is a last resort

On January 19, BeiGene's U.

Newly appointed chairman and CEO Kenneth Galbraith said 10 members of the former senior management team (or 50%, including chief people officer, chief commercial officer and chief scientific officer, etc.

In addition, in line with the staffing adjustment of the senior management team, there will be a company-wide reduction in staff, with the goal of reducing the total number of employees by at least 25% by the end of 2022

On Jan.

It is reported that the reorganization was made after Wanchun Pharmaceutical received a complete reply letter to the FDA's new drug application in November last year

Plinabulin is the first product under development of Wanchun Pharmaceutical after its establishment, and it is also the first product to be declared for listing

In addition, innovative pharmaceutical companies such as Unity Biotechnology, Gamida Cell, Kaleido Biosciences, and Spectrum Pharmaceuticals have all announced plans to streamline personnel, saving money, prolonging lifespan, and betting on the most promising track for the common purpose

03 Normalization of personnel adjustment

In fact, in recent years, under the background of accelerating changes in the pharmaceutical landscape, whether it is a multinational pharmaceutical company or a local pharmaceutical company, staff reduction, executive changes, and business adjustments have become normal actions

Under the pressure of performance, multinational pharmaceutical companies need to make corresponding business adjustments, and the pressure faced by local traditional pharmaceutical companies is also not small

Taking Hengrui as an example, since 2018, Hengrui has entered a total of 28 types of generic drugs that have been centrally purchased by the state, and 18 were selected
.
Under the circumstance that the development of innovative drug business still takes longer, Hengrui Medicine clearly mentioned in the 2021 semi-annual report that it needs to "strengthen the troops and simplify the administration"
.

The impact isn’t just for lower-level sales reps.
Changes in pharma executives are also common in 2021
.
According to media statistics, more than 300 senior executives of pharmaceutical companies will leave in 2021, involving many chairman and presidents
.
Entering 2022, personnel adjustments are still frequent, with nearly 30 executives of pharmaceutical companies resigning in January alone
.

At the same time, the problems of the domestic innovative biopharmaceutical industry have gradually emerged, the homogenization competition is serious, and the biopharmaceutical innovation is facing severe challenges
.
The risk of new drug research and development is high.
With the decline of capital in the pharmaceutical industry, local innovative biopharmaceutical companies will eventually face the same funding problems as foreign innovative pharmaceutical companies
.
In order to achieve long-term development, due to the intensity of domestic competition, staff reduction may become the final choice for many companies
.

However, despite the fierce market competition, development and advancement are still the main theme of the pharmaceutical industry, and many professionals are needed in this process
.
Only by adjusting its own capabilities and adapting to the new industry needs can it go through this adjustment period smoothly
.